dexametazona zentiva 4 mg
zentiva s.a. - romania - dexamethasonum - compr. - 4mg - corticosteroizi sistemici glucocorticoizi
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mielom multiplu - agenți antineoplazici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
ducressa 1 mg/ml+5 mg/ml
santen oy - finlanda - combinatii (dexamethasonum+levofloxacinum) - pic. oft., sol. - 1mg/ml+5mg/ml - antiinflamatoare si antiinfectioase in combinatie corticosteroizi si antiinfectioase in combinatie
tobradex
alcon-couvreur n.v. - belgia - combinatii (tobramycinum+dexamethasonum) - ung. oft. - 3mg/1mg/g - antiinflamatoare si antiinfectioase in combinatie corticosteroizi si antiinfectioase in combinatie
l-dexopt 5 mg/1 mg/ml picături oftalmice, soluţie
llc rompharm company georgia - levofloxacinum+dexamethasoni phosphatum - picături oftalmice, soluţie - 5 mg/1 mg/ml
bortezomib glenmark 3,5 mg
synthon hispania s.l. - spania - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
zegomib 1 mg
synthon s.r.o. blansko - spania - bortezomibum - pulb. pt. sol. inj. - 1mg - alte antineoplazice alte antineoplazice
zegomib 3,5 mg
synthon s.r.o. blansko - spania - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
bortega 3,5 mg
pharmidea sia - letonia - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
bortezomib teva 1 mg
teva pharmaceuticals s.r.l. - bortezomibum - pulb. pt. sol. inj. - 1mg - alte antineoplazice alte antineoplazice